PHILADELPHIA, June 12, 2014 /PRNewswire/ --
Amirsys' point-of-care decision support technology to augment Elsevier's evidence-based clinical solutions suite
Focused on visually oriented medical disciplines like radiology, pathology and anatomy, Amirsys' global solutions give healthcare providers the expert information and clinical decision support (CDS) tools to make informed, expert and evidence-based diagnoses. Amirsys also provides learning environments that help those training in these disciplines to sharpen their diagnostic skills and increase their knowledge.
"This acquisition bolsters Elsevier's comprehensive set of point-of-decision solutions, providing our customers around the world with a greater ability to improve the quality of care and patient outcomes," said Jay Katzen, President, Elsevier Clinical Solutions. "In addition, because radiology, pathology, anatomy and their associated content and data-rich images are foundational elements of other disciplines, we believe Amirsys will improve our ability to better inform diagnostic and treatment decisions across a broad scope of other specialties."
Amirsys also created sophisticated technology tools to develop and maintain current imaging content, and Elsevier expects to be able to adapt those tools to serve other visually rich specialties. Amirsys products include STATdx, RADPrimer, ImmunoQuery, AnatomyOne and Amirsys Imaging, Pathology, and Anatomy Reference Centers. Amirsys will be integrated with the Elsevier Clinical Solutions suite, which includes clinical workflow and decision support, clinical reference and patient engagement, including ClinicalKey, CPM CarePoints, ExitCare, and InOrder by Elsevier.
"Elsevier is known for our trusted, evidence-based content, and the Amirsys team, products and solutions add substantial global expertise and technology to our suite of solutions," Katzen said. "The Amirsys content development and technology platform enhances our ability to frequently update and manage images and text assets throughout our clinical solutions suite so that our customers always have access to the most current content available."
Amirsys will continue its tradition of publishing new radiology and pathology reference texts with Elsevier. Amirsys' new editions and titles, publishing group and world-renowned author teams will complement Elsevier's own portfolio of high quality radiology and pathology titles.
"We are excited to become part of Elsevier's premier suite of clinical solutions," said Paul Scholtes, co-CEO of Amirsys. "Together we address the needs of radiology and diagnostic pathology professionals, hospitals, and physicians' practices whose clinicians must have the best information and technology in order to deliver a quality diagnosis," said Ric Harnsberger, MD, co-CEO of Amirsys.
Amirsys is headquartered in Salt Lake City, Utah. The acquisition is effective immediately and financial terms of the transaction are not being disclosed.
Amirsys, Inc. is a leading provider of innovative healthcare information solutions in radiology, pathology, and anatomy. Amirsys' unique combination of proprietary technology and image-intensive, evidence-based content provide online problem-solving solutions and reference books to thousands of physicians and health professionals worldwide. Amirsys delivers medical expertise with powerful technology to provide life-saving, vital information to healthcare professionals. Amirsys content is authored by a team of over 300 leading radiologists, pathologists, and anatomists.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions - among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey - and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world-leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Director, Corporate Relations